Francesco Saverio Brunetti
Overview
Explore the profile of Francesco Saverio Brunetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiefari E, Arcidiacono B, Mirabelli M, Brunetti F, Greco E, Foti D, et al.
Methods Mol Biol
. 2021 Jun;
2324:187-202.
PMID: 34165716
One of the most commonly described biological feature of processed pseudogenes is the ability to influence the expression of their parental coding genes. As evidenced in several studies, the high...
2.
Di Vito A, Donato A, Presta I, Mancuso T, Brunetti F, Mastroroberto P, et al.
Int J Mol Sci
. 2021 Jan;
22(2).
PMID: 33477599
Calcific Aortic Valve Disease (CAVD) is the most common valvular heart disease in developed countries and in the ageing population. It is strongly correlated to median age, affecting up to...
3.
Mirabelli M, Chiefari E, Arcidiacono B, Corigliano D, Brunetti F, Maggisano V, et al.
Nutrients
. 2020 Apr;
12(4).
PMID: 32290535
Insulin resistance (IR), defined as an attenuated biological response to circulating insulin, is a fundamental defect in obesity and type 2 diabetes (T2D), and is also linked to a wide...
4.
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli M, Chiefari E, Caroleo P, Arcidiacono B, Corigliano D, Giuliano S, et al.
Int J Environ Res Public Health
. 2020 Jan;
17(1).
PMID: 31892206
: Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes...
5.
Mirabelli M, Chiefari E, Caroleo P, Vero R, Brunetti F, Corigliano D, et al.
J Diabetes Res
. 2019 Nov;
2019:3971060.
PMID: 31781664
Background: SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the long-term effectiveness...
6.
Greco M, Arcidiacono B, Chiefari E, Vitagliano T, Ciriaco A, Brunetti F, et al.
Anticancer Res
. 2018 Jan;
38(2):771-778.
PMID: 29374701
Background/aim: The High-Mobility Group A1 (HMGA1) protein has been implicated in human malignancies, playing an important role in cancer proliferation, angiogenesis and metastasis. Increased HMGA1 expression has been found in...
7.
Chiefari E, Arcidiacono B, Possidente K, Iiritano S, Ventura V, Pandolfo R, et al.
PLoS One
. 2013 Dec;
8(12):e83969.
PMID: 24367622
The High-Mobility Group AT-Hook 1 (HMGA1) protein is an architectural transcription factor that binds to AT-rich sequences in the promoter region of DNA and functions as a specific cofactor for...